Cancer Immunology Community Seeks Better End Points
Nov 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.